All Updates

All Updates

icon
Filter
Partnerships
Burning Rock Biotech collaborates with Bayer to develop NGS-based CDx solutions in China
Precision Medicine
May 30, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Regulation/policy
Product updates
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
Precision Medicine

Precision Medicine

May 30, 2024

Burning Rock Biotech collaborates with Bayer to develop NGS-based CDx solutions in China

Partnerships

  • Burning Rock Biotech has partnered with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) to enable treatment choices for cancer patients in China.

  • The partnership aims to advance CDx products in China, targeting Bayer's expanding range of precision cancer treatments. Burning Rock states that by combining resources and expertise in cancer diagnosis and treatment, the collaboration is aimed to set a benchmark standard for precision oncology in China. 

  • Burning Rock is a biotechnology company specializing in applying NGS technology in precision oncology. Its services encompass NGS-based therapy selection testing for late-stage cancer patients, global pharmaceutical services for biomarker detection and CDx solutions development, and early cancer detection.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.